(A) Evaluation of overall survival with the protein biomarker level at
last dose (CA125, CEA, CA19–9, or PSA). A significant inverse correlation
was observed between the overall survival in months when compared to the
residual protein biomarker (r=-0.67, p=<0.001; Pearson correlation). (B)
Kaplan-Meier curves for overall survival among patients with tissue enrollment
status of MSI and detectable protein biomarker levels (n=45). For patients with
two consecutive timepoints with >75% reduction in protein biomarker
levels, landmarked 3.5–7 weeks post treatment initiation (n=12), median
overall survival was not reached. For patients with ≤75% reduction in
protein biomarker levels (n=33), median overall survival was 35.1 months. (C)
Evaluation of overall survival compared to residual MSI allele levels at last
dose. A significant inverse correlation was observed between the overall
survival when compared to the residual MSI allele levels (r=-0.91,
p=<0.001; Pearson correlation). (D) Kaplan-Meier curves for overall
survival among patients with tissue enrollment status of MSI and detectable MSI
status at baseline (n=9). For patients with two consecutive timepoints
displaying no residual MSI alleles (n=4) median overall survival was not
reached. For patients with multiple timepoints containing residual MSI alleles
(n=5) median overall survival was 7.64 months. (E) Evaluation of overall
survival compared to residual TMB levels at last dose. A significant inverse
correlation was observed between the overall survival in months when compared to
the residual TMB levels (r=-0.95, p=<0.001; Pearson correlation). (F)
Kaplan-Meier curves for overall survival among patients with tissue enrollment
status of MSI and detectable TMB levels at baseline (n=11). For patients with
>90% reduction in TMB levels (n=4), median overall survival was not
reached. For patients with ≤90% reduction in TMB levels (n=7), median
overall survival was 7.64 months. “/” indicates a censored
datapoint; “*” indicates cases where baseline protein biomarker,
MSI or TMB was not detected and were not included in the subsequent analyses; In
cases where residual protein biomarker, MSI or TMB levels increased when
compared to baseline, values of greater than 100% are indicated.